Emerging Drug Developer: Tengion

Emerging Drug Developer: Tengion

While most emerging biotech companies are consumed by the demands of clinical trials, Tengion built a manufacturing center to assist with its mid-stage studies of the neo-bladder. The developer is building new bladders for patients using their own cells to seed replacement organs. The science was advanced by an expert in the field of regenerative medicine and Tengion has its eye on taking this product all the way through to commercialization. With some major league venture backing, they are well on their way. Article

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.